Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza
2021 · npj Vaccines · 110 citations
https://doi.org/10.1038/s41541-021-00420-6
S
Shrirang Karve
Sanofi (France)(FR)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
42
Papers
1.3K
Citations
19
h-index
21
i10-index
Shrirang Karve is an academic researcher from Sanofi (France). The author has contributed to research in topics: RNA Interference and Gene Delivery & Nanoparticle-Based Drug Delivery & Animal Virus Infections Studies. The author has an h-index of 19, co-authored 36 publications.
ORCID: 0000-0002-9433-3089Papers by this author
worksImmunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models
2021 · npj Vaccines · 82 citations
https://doi.org/10.1038/s41541-021-00324-5
Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model
2022 · Vaccine · 10 citations
https://doi.org/10.1016/j.vaccine.2022.01.021
1303P METPRO: Evaluating prognostic value of c-Met protein overexpression and concurrent biomarker presence
2024 · Annals of Oncology · 1 citations
https://doi.org/10.1016/j.annonc.2024.08.1360
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat